Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05547321
Title Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors.
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Oncomatryx Biopharma S.L.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ESP


No variant requirements are available.